Antithrombotic Anticoagulants

Acute coronary syndromes

Thienopyridine Pretreatment in Non ST Elevation ACS syndrome

Original title: Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and...

solaci - 16 December, 2014

Learn More

Antithrombotic Anticoagulants

Greater platelet reactivity in diabetic patients receiving DES and clopidogrel

Original title: Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients...

solaci - 20 October, 2014

Learn More

Antithrombotic Anticoagulants

Resistance to Aspirin Associated to Greater Risk of In-Stent Thrombosis and Death

Original title: Aspirin Treatment and Outcomes After Percutaneous Coronary InterventionResults of the ISAR-ASPI Registry. Reference: Katharina Mayer et al. J...

solaci - 29 August, 2014

Learn More

Antithrombotic Anticoagulants

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Original title: Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug...

solaci - 24 June, 2014

Learn More

Acute coronary syndromes

Higher event rate in those with non-ST elevation ACS who received revascularization at PLATO study. Beyond this, ticagrelor reduced mortality.

Original title: Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from...

solaci - 7 May, 2014

Learn More

Antithrombotic Anticoagulants

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months...

solaci - 25 February, 2014

Learn More

Acute coronary syndromes

Almost 40 % of those who initially receive clopidogrel then switch to prasugrel or ticagrelor in clinical practice.

Original title: In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary...

solaci - 7 February, 2014

Learn More

Antithrombotic Anticoagulants

Stent reestenosis, the only subgroup that benefits from longer double antiaggregation

Original title: Short vs. Long Term Duration of Dual Antiplatelet Therapy in Patients treated for InstentRestenosis. A PRODIGY...

solaci - 13 December, 2013

Learn More

Thienopyridine Pretreatment in Non ST Elevation ACS syndrome

Greater platelet reactivity in diabetic patients receiving DES and clopidogrel

Resistance to Aspirin Associated to Greater Risk of In-Stent Thrombosis and Death

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Higher event rate in those with non-ST elevation ACS who received revascularization at PLATO study. Beyond this, ticagrelor reduced mortality.

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Almost 40 % of those who initially receive clopidogrel then switch to prasugrel or ticagrelor in clinical practice.

Stent reestenosis, the only subgroup that benefits from longer double antiaggregation

Last News

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

Long Term Results of the International Chimney Registry

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

Institutional News

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

Check out the best images of the El Salvador 2024 Sessions

The El Salvador 2024 Sessions are coming soon

Access